Domestic developed COVID-19 vaccine has entered the final stage of commercialization. A candidate for the COVID-19 vaccine developed by SK Bioscience will conduct phase 3 clinical trial.

The MFDS announced on Tuesday that it approved phase 3 clinical trial plan for the first domestic COVID-19 vaccine after thoroughly verifying its safety and scientific feasibility.

With the approval, COVID-19 vaccine developed by a Korean company will enter phase 3 clinical trial for the first time. GBP510 is a recombinant vaccine that injects surface antigen protein of the coronavirus created using genetic recombination technology to induce immune response, stimulating immune cells in the body and neutraliz